Atyr Pharma Inc
ATYR - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$12.11M
Close$
$-0.81
116.4% downside
Current Fair Value
116.4% downsideOvervalued by 116.4% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $12.11 Million |
|---|---|
| Enterprise Value | $7.25 Million |
| Earnings per Share | $-32 |
| Beta | 0.53 |
| Outstanding Shares | 2,451,748 |
Return
| Return on Equity | -124.64% |
|---|---|
| Return on Assets | -87.08% |
| Return on Invested Capital | -109.29% |
Valuation & Multiples
| P/E Ratio | -0.2 |
|---|---|
| PEG | 0.42 |
| Price to Sales | - |
| Price to Book Ratio | 0.26 |
| Enterprise Value to Revenue | 38.16 |
| Enterprise Value to EBIT | -0.11 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 1.56 |
| Debt to Equity | 0.23 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-0.13
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-4.00
Consensus analyst estimateRevenue Estimate
$2.50 M
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Atyr Pharma Inc
80 employees
CEO: Sanjay Shukla
atyr pharma (nasdaq: life) is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe rare diseases using its knowledge of physiocrine biology, a newly discovered set of physiological ...